Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539805 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL31677367 | 0.81 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL938253 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| Pyridine SCHEMBL28238577 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB4LMNA | |
| SCHEMBL30471555 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL31677378 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL9001366 | 0.80 | ALDH1A1 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL31267692 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL17742269 | 0.79 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL5186748 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606902-A1 | PREPARATION OF ENANTIO-SPECIFIC EPOXIDES | Vilnius University (LT) | 2025-08-27 | — | — | EP | disclosed |
| CN-114036878-A | Dual neuromorphic device based on charge trapping effect and electric double-layer effect and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2022-02-11 | — | — | CN | disclosed |
| US-6846817-B2 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030027810-A1 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | disclosed |
| US-6159654-A | Negative photosensitive polymer composition of a thermosetting polymer precursor curable by cyclodehydration upon heating | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-12-12 | — | — | US | disclosed |
| WO-2000073269-A2 | NICOTINE RECEPTOR LIGANDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027810-A1 | Nicotine receptor ligands | CHRNA1, CHRNB1, CHRNA9 | CHRNB2 22/4885CHRNA4 12/4885CHRNA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.